ArticleACG case reports journal2026
Intrahepatic Lymphedema Presenting With Abnormal Bilirubin Metabolism as the Initial Manifestation.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic lymphedema is a rare condition usually associated with hepatobiliary diseases, cardiogenic factors, pancreatic disorders, or malignant lymph node lesions. This report describes a unique case of intrahepatic lymphedema presenting with abnormal bilirubin metabolism as the initial manifestation, with no identical cases identified in the China National Knowledge Infrastructure (CNKI), Wanfang Database, or PubMed. The patient was a 30-year-old Chinese man admitted due to fatigue, anorexia, and yellowish urine for 3 days. Physical examination revealed mild generalized jaundice without hepatosplenomegaly or signs of chronic liver disease. Laboratory tests showed marked elevation of total bilirubin (347.1 μmol/L), direct bilirubin (241.7 μmol/L), and indirect bilirubin (105.4 μmol/L), while viral hepatitis markers (Hepatitis B Virus DNA, Hepatitis C Virus RNA, Human Immunodeficiency Virus RNA) and autoimmune antibody panels were negative. Abdominal computed tomography (CT) demonstrated dilated lymphatic vessels around the intrahepatic portal vein without extrahepatic biliary obstruction or cardiac dysfunction. Intravenous methylprednisolone sodium succinate (40 mg/d) was initiated as exploratory treatment since autoimmune hepatitis could not be excluded. Jaundice improved significantly after 4 days, with the dose reduced to 20 mg/d. By day 8 of treatment, total bilirubin decreased to 112 μmol/L and liver CT showed regression of lymphatic dilation. At the 14-day follow-up, all biochemical indicators had normalized and CT abnormalities resolved; liver biopsy was not performed due to the patient's refusal and rapid clinical response to glucocorticoids. This case suggests that exploratory treatment with glucocorticoids (e.g., methylprednisolone sodium succinate) may be effective for patients with unexplained intrahepatic lymphedema and abnormal bilirubin metabolism, especially when an immune-mediated etiology is suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.